Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.61 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17956756 | 0.80 | GAA (0.71) | LMNASMN1; SMN2HPGDGAAALDH1A1 | |
| SCHEMBL25517519 | 0.79 | HPGD (0.63) | LMNASMN1; SMN2HPGDGAAALDH1A1 | |
| SCHEMBL31388324 | 0.78 | HPGD (0.80) | LMNANPSR1SMN1; SMN2HPGDGAA | |
| SCHEMBL3822985 | 0.78 | HPGD (0.80) | LMNANPSR1SMN1; SMN2HPGDGAA | |
| SCHEMBL7945600 | 0.78 | ALDH1A1 (0.62) | LMNASMN1; SMN2HPGDGAAALDH1A1 | |
| SCHEMBL6816152 | 0.77 | KMT2A (0.71) | LMNASMN1; SMN2HPGDGAAALDH1A1 | |
| SCHEMBL5458347 | 0.74 | RAB9A (0.61) | LMNANPSR1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL7945596 | 0.74 | SMN1; SMN2 (0.76) | LMNASMN1; SMN2HPGDGAAALDH1A1 | |
| SCHEMBL3307714 | 0.73 | RAB9A (0.60) | LMNANPSR1SMN1; SMN2HPGDALDH1A1 | |
| SCHEMBL3307712 | 0.73 | RAB9A (0.60) | LMNANPSR1SMN1; SMN2HPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | Shenzhen Bay Laboratory (CN) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230157996-A1 | SMALL-MOLECULE INHIBITOR TARGETING EB VIRUS NUCLEAR ANTIGEN PROTEIN, PREPARATION METHOD AND USE THEREOF | SSB, EBNA1BP2, PML | LMNA 822/4885NPSR1 4384/4885SMN1; SMN2 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.